The psychotherapeutic potential of MDMA (3,4-methylenedioxymethamphetamine): an evidence-based review.
AIMS AND RATIONALE: The purpose of this study was to review whether methylenedioxymethamphetamine (MDMA) has the appropriate pharmacodynamic profile to be a therapeutic agent.


METHODS
Empirical descriptions of MDMA's subjective effects in humans will be reviewed to evaluate the proposal that MDMA has psychotherapeutic properties. The focus will be published evidence on its functional effects in therapeutic, medical, and other situations.


RESULTS
MDMA is a powerful central nervous system (CNS) stimulant which affects several neurotransmitter systems and intensifies a range of psychobiological functions. Its acute mood effects can be very positive and life enhancing, and the affirmative cognitions engendered during MDMA therapy may well endure afterwards. However, MDMA also has a number of potential anti-therapeutic characteristics. Acutely, it can also intensify negative cognitions, and these may similarly endure over time. Psychotherapists have found that setting, intention, and expectancy are crucial for a positive outcome, but these factors cannot be guaranteed. Post-MDMA, there is a period of neurotransmitter recovery when low moods predominate, and these may exacerbate psychiatric distress. The explanations proposed for MDMA-assisted therapy are all psychodynamic, and a neurochemical model needs to be outlined. It has been suggested that enduring therapeutic gains can follow a single session, but again, this lacks a clear psychopharmacological rationale. Finally, diathesis-stress models suggest that psychiatric individuals are more prone to acute and chronic abreactions to CNS stimulants such as MDMA.


CONCLUSIONS
There are a number of issues which need to be addressed before it can be argued that MDMA might be clinically useful for psychotherapy.
Parrott
A C
AC
Department of Psychology, University of Wales Swansea, Swansea, SA2 8PP, Wales, UK. a.c.parrott@swansea.ac.uk
D000697:Central Nervous System Stimulants / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D006213:Hallucinogens / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy*; D008954:Models, Biological; D018817:N-Methyl-3,4-methylenedioxyamphetamine / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D009434:Neural Pathways / Q000187:drug effects; D018579:Patient Selection; D011613:Psychotherapy / Q000379:methods; D018490:Serotonin Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*
D000697:Central Nervous System Stimulants; D006213:Hallucinogens; D018490:Serotonin Agents; D018817:N-Methyl-3,4-methylenedioxyamphetamine